#bcsm
LightNews LightNews
breezy413.bsky.social
#Music m.youtube.com/watch?v=BCSm...
Boom Shakalaka
YouTube video by C-Steezee - Topic
m.youtube.com
October 28, 2026 at 2:25 AM
joatmnb.bsky.social
Did you know tamoxifen can trigger eye problems? Learn why opthalmologists are concerned with MNB medicalnewsbulletin.com/bulletin-boo... 🧪 🩺 CanSky, OncoSky 🩺📊 medsky public health #women'shealth #HRPositiveBreastCancer #BCSM #TamoxifenSideEffects #aromataseinhibitor #tamoxifen
On Tamoxifen? Schedule a Retinal Exam At Your Next Eye Visit | Medical News Bulletin
Did you know women using tamoxifen to treat breast cancer are at higher risk of eye issues like retinopathy? Learn more with MNB
medicalnewsbulletin.com
November 2, 2026 at 12:25 PM
dianeheditsian.bsky.social
news.stanford.edu/stories/2026... #BCSM
How mental health and cancer survivorship intersect
Researchers discuss a new study linking mental health disorders to poorer cancer survival – and why support should extend beyond initial treatment.
news.stanford.edu
October 30, 2026 at 2:05 PM
onclive.bsky.social
🎧 On this episode of #BreastCancerBriefing, Sara Nunnery, MD, and Hil Moss, MBA, MPH, discuss gaps in breast cancer survivorship care. #bcsm #breastcancerawarenessmonth #oncology

Watch on our site or listen on your favorite podcast platforms!

www.onclive.com/view/breast-...
October 30, 2026 at 1:51 PM
alliance-org.bsky.social
Alliance Foundation Trials and Natera have launched AFT-70 NAVIGATE, a global Phase III trial in ER+/HER2- early-stage breast cancer, evaluating giredestrant, Genentech’s investigational oral SERD, with Signatera MRD-guided CDK4/6 inhibitor therapy: https://bit.ly/AFT70 #BCSM
October 30, 2026 at 6:00 PM
onclive.bsky.social
👀 @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, discusses the @fda.gov approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring. #bcsm #oncology

Read more ➡️: www.onclive.com/view/camizes...
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer | OncLive
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
www.onclive.com
November 2, 2026 at 10:39 PM
onclive.bsky.social
📰 The European Commission has approved T-DXd monotherapy for patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment with a taxane and HER2-directed therapy. #bcsm #oncology

Read more ➡️: www.onclive.com/view/t-dxd-g...
October 27, 2026 at 2:19 PM
onclive.bsky.social
WATCH 🎥: Federica Gatti, MD, discusses the prognostic impact of ESR1 mutations and genomic co-alterations in HR+/HER2– metastatic breast cancer. #bcsm #oncology

Full video ➡️: www.onclive.com/view/dr-gatt...
Dr Gatti on the Prognostic Impact of ESR1 Mutations and Co-Alterations in Breast Cancer | OncLive
Federica Gatti, MD, discusses the prognostic impact of ESR1 mutations and genomic co-alterations in HR+/HER2– metastatic breast cancer.
www.onclive.com
October 31, 2026 at 12:56 AM
alliance-org.bsky.social
Now enrolling! The #REVITALIZE study (Alliance A221801) is testing laser therapy to relieve chronic vaginal dryness, a common but overlooked side effect of breast cancer treatment. 💗🧪 #BCSM https://bit.ly/REVITALIZE2026 #womenshealth #breastcancer
October 28, 2026 at 2:00 PM
onclive.bsky.social
T-DXd plus pertuzumab improved systemic and intracranial outcomes vs THP in pts w/ HER2-positive advanced or metastatic breast cancer and brain metastases in an exploratory analysis of DESTINY-Breast09. @myesmo.bsky.social #ESMO2026 #bcsm #oncology

Full story ➡️: www.onclive.com/view/t-dxd-p...
October 29, 2026 at 2:06 AM
andrewtheblueskier.bsky.social
kajkavski and čakavski have mistakenly been grouped as registers of BCSM but they're hardly such a thing, as a native speaker. štokavski describes both the standards and all the other too-small variations from it
October 24, 2026 at 4:26 PM
onclive.bsky.social
📰 Trastuzumab pamirtecan delivered a statistically significant yet modest PFS improvement vs chemotherapy in patients with HR+, HER2-low metastatic breast cancer. #bcsm #oncology

Full story ➡️: www.onclive.com/view/trastuz...
Trastuzumab Pamirtecan Improves PFS in HR+, HER2-Low Metastatic Breast Cancer | OncLive
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
www.onclive.com
October 26, 2026 at 3:25 PM
onclive.bsky.social
Dato-DXd improved CNS PFS and IC response vs investigator's choice of chemotherapy in locally recurrent inoperable or metastatic TNBC and baseline brain metastases for whom IO was not an option #ESMO26 #bcsm #oncology

Dive into the TROPION-Breast02 subgroup data: www.onclive.com/view/first-l...
October 24, 2026 at 5:52 PM
onclive.bsky.social
📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a DESTINY-Breast11 analysis. @myesmo.bsky.social #ESMO2026 #bcsm #oncology

Read more: www.onclive.com/view/t-dxd-f...
October 24, 2026 at 2:12 PM
onclive.bsky.social
Adjuvant giredestrant sustained physical functioning, role functioning, and HRQOL and was associated with sustained low AE bother vs SOC in ER+, HER2– early breast cancer, according to PROs from lidERA Breast Cancer. @myesmo.bsky.social #ESMO2026 #bcsm #oncology

www.onclive.com/view/adjuvan...
October 23, 2026 at 6:55 PM
onclive.bsky.social
📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial

Read more here ➡️: www.onclive.com/view/panku-b...

#bcsm #oncology #ESMO26 @myesmo.bsky.social
Iza-Bren Significantly Improves PFS vs Chemotherapy in Pretreated HR+/HER2– Advanced Breast Cancer | OncLive
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
www.onclive.com
October 24, 2026 at 12:45 PM
cancertherapyadv.bsky.social
3 #BreastCancer Stats Every HCP Needs to Know in 2026 for #BCAM 📊

🔹 91.9% overall 5-year survival rate
🔹 +1.4% annual rise in cases under age 50
🔹 -44% drop in mortality rates since 1989

🔗 Read the full report: https://bit.ly/4BjvRBF

#bcsm #BreastCancerAwarenessMonth
A stylized image of cancer cells next to bold text reading, "3 Cancer Stats Every Healthcare Professional Needs to Know in 2026." A prompt below says, "Swipe to reveal the latest data." The Cancer Therapy Advisor logo is at the bottom right. Overall 5-year breast cancer survival rate at 91.9%, with localized stage diagnoses exceeding 99%. Emphasizes the importance of early screening. Source: SEER Program, 2016–2022, Cancer Therapy Advisor, 2026. Image includes a stethoscope and the Cancer Therapy Advisor logo. A graphic titled "Rise in Early-Onset Diagnoses: +1.4%" shows a chart with orange and blue bars. Text describes the increase in breast cancer incidence in individuals under age 50 by 1.4% per year over the past decade, surpassing the 0.7% increase in those 50 and older. Source: American Cancer Society & Cancer Therapy Advisor Data, 2026. Cancer Therapy Advisor logo is displayed. Red image with the text "Long-Term Mortality Decline: -44%." It states breast cancer-related deaths have decreased by 44% since 1989 due to advancements in therapies and detection. Source noted as American Cancer Society & Cancer Therapy Advisor, 2026. Includes a small image of pink and white cells on a blue background. Logo: Cancer Therapy Advisor.
October 26, 2026 at 7:21 PM
oncoalert.bsky.social
🎗️ #ESMO26 Breast Cancer: Top Ten by OncoAlert

Our faculty picked the 10 must-know breast cancer abstracts from Madrid 🧵👇

#bcsm #OncoSky
October 20, 2026 at 9:57 AM
onclive.bsky.social
The FDA has granted 510(k) clearance to TumorSight Risk, an AI-based software that estimates 5- and 10-year RFS from routine breast MRI, pathology, and clinical data for patients with HR+ HER2–, stage I to IIIA breast cancer. #bcsm #oncology

www.onclive.com/view/fda-cle...
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer | OncLive
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
www.onclive.com
October 19, 2026 at 7:28 PM
onclive.bsky.social
🎥 Megan Kruse, MD, of @clevelandclinic.bsky.social, discusses the potential utility of FES-PET/CT in lobular breast cancer for Global Lobular Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology

Read on for more lobular disease insights ➡️: www.onclive.com/view/refined...
October 15, 2026 at 6:28 PM
onclive.bsky.social
In this episode of #OncologyUnplugged, Chandler Park, MD, and Jame Abraham, MD, discuss breast cancer management & the role of AI. @clevelandclinic.bsky.social #bcsm #oncology

Watch on our site or listen on your favorite podcast platforms!

www.onclive.com/view/biology...
October 15, 2026 at 6:15 PM
onclive.bsky.social
❓FAQ ❓: Sara Nunnery, MD, and Annie Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment. #BreastCancerBriefing #bcsm #oncology

Read more ➡️: www.onclive.com/view/frequen...
Frequently Asked Questions on Breast Cancer Patient Support, Self-Advocacy, and Survivorship | OncLive
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
www.onclive.com
October 16, 2026 at 3:49 PM
jco-asco.bsky.social
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911

Read the article. https://bit.ly/3VGspka
#BreastCancer #bcsm
October 14, 2026 at 7:00 PM
emilydrake.ca
Q4: What are the next steps for #AYACancer innovation? #AYACSM

#GYNCSM #ONCOLOGY #CANCERRESEARCH #TYACANCER #BTSM #BCSM #LCSM
October 14, 2026 at 12:46 AM
wileyhealth.bsky.social
Revisit the 2025 American Cancer Society report providing statistics on lobular breast cancer in the United States: https://bit.ly/4j6HFAI

The article is also featured in Wiley's #BreastCancerAwareness collection: https://bit.ly/3VNLroL

@americancancersoc.bsky.social
#BCAM #BCSM 🩷
This Breast Cancer Awareness Month, revisit the 2025 American Cancer Society report providing statistics on lobular breast cancer in the United States.
October 15, 2026 at 1:00 PM